In addition, independent of PD‐L1 expression or TMB status, PAPPA2 mutation displayed a strong association with better clinical outcomes in patients with NSCLC and SKCM after receiving ICIs therapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.